{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:13:44Z","timestamp":1768263224271,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clindermatol.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T23:46:18Z","timestamp":1612309578000},"page":"359-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of COVID-19 on autoimmune blistering diseases"],"prefix":"10.1016","volume":"39","author":[{"given":"Kossara","family":"Drenovska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snejina","family":"Vassileva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Tanev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2021.01.007_bib0001","first-page":"E013","article-title":"Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing [in Chinese]","volume":"43","author":"Zhang","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0002","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0003","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.3390\/ijms21093330","article-title":"Cytokine release syndrome in COVID-19 patients, A new scenario for an old concern: the fragile balance between infections and autoimmunity","volume":"21","author":"Picchianti Diamanti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0004","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/ijd.15189","article-title":"Covid-19 pandemic and the skin","volume":"59","author":"Drenovska","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0005","doi-asserted-by":"crossref","first-page":"e13430","DOI":"10.1111\/dth.13430","article-title":"Challenges of COVID-19 pandemic for dermatology","volume":"33","author":"Wollina","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.revmed.2013.04.016","article-title":"Autoimmune blistering diseases [in French]","volume":"35","author":"Duvert-Lehembre","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0007","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0008","first-page":"1","article-title":"New strategies in the treatment of pemphigus [in Bulgarian]","volume":"5","author":"Drenovska","year":"2011","journal-title":"Medinfo"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0010","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2 K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/17512433.2019.1670059","article-title":"What is novel in the clinical management of pemphigus","volume":"12","author":"Bilgic","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0012","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1111\/ajd.13414","article-title":"Management of patients with pemphigus vulgaris during the COVID-19 pandemic: experience of a second level dermatology center","volume":"62","author":"Diotallevi","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0013","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1111\/jdv.16491","article-title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","volume":"34","author":"Di Altobrando","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0014","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1111\/jdv.16578","article-title":"Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus","volume":"34","author":"Balestri","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0015","doi-asserted-by":"crossref","first-page":"e14398","DOI":"10.1111\/dth.14398","article-title":"Aggressive course of pemphigus vulgaris following COVID-19 infection","volume":"33","author":"Ghalamkarpour","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0016","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.13823","article-title":"Paradoxical worsening of pemphigus vulgaris following rituximab therapy","volume":"173","author":"Feldman","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bjd.19266","article-title":"Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy","volume":"183","author":"Carugno","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0018","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2020.04.044","article-title":"Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients","volume":"83","author":"Marzano","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0019","first-page":"e51","article-title":"Management of pemphigus in COVID-19 pandemic era; a review article","volume":"8","author":"Abdollahimajd","year":"2020","journal-title":"Arch Acad Emerg Med"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0020","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.jaad.2020.04.005","article-title":"Treatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"82","author":"Shakshouk","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0021","doi-asserted-by":"crossref","unstructured":"Pathania Y.S., Bhardwaj A. Treatment of severe pemphigus vulgaris during COVID-19 pandemic. J Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1801971.","DOI":"10.1080\/09546634.2020.1801971"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0022","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0023","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","article-title":"Rituximab as first-line treatment of pemphigus","volume":"389","author":"Schmidt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0025","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jaad.2020.09.002","article-title":"Authors\u2019 reply to the comment \u201cTreatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"84","author":"Shakshouk","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clindermatol.2021.01.007_bib0026","doi-asserted-by":"crossref","first-page":"A75","DOI":"10.1016\/j.annder.2020.09.011","article-title":"Incidence and prognosis of COVID-19 in patients with autoimmune bullous diseases [in French]","volume":"147","author":"Aouar","year":"2020","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0027","doi-asserted-by":"crossref","unstructured":"Di Altobrando A, Patrizi A, Abbenante D, Bardazzi F. Rituximab: a safe therapeutic option during the COVID-19 pandemic?J Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1800565.","DOI":"10.1080\/09546634.2020.1800565"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0028","doi-asserted-by":"crossref","first-page":"e14188","DOI":"10.1111\/dth.14188","article-title":"Treatment of pemphigus patients in the COVID-19 era: a specific focus on rituximab","volume":"33","author":"Mahmoudi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0029","series-title":"Guidance on the use of biologic agents during COVID-19 outbreak","year":"2020"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0030","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2020.07.132","article-title":"Reply to \u201cTreatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"84","author":"Schultz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0031","doi-asserted-by":"crossref","unstructured":"Shahidi-Dadras M, Abdollahimajd F, Ohadi L, et\u00a0al. COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience. Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1789041.","DOI":"10.1080\/09546634.2020.1789041"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0032","doi-asserted-by":"crossref","unstructured":"Waldman RA, Creed M, Sharp K, et\u00a0al. Letter in reply: Toward a COVID-19 vaccine strategy for pemphigus patients on rituximab. J Am Acad Dermatol, in press. doi:10.1016\/j.jaad.2020.10.075.","DOI":"10.1016\/j.jaad.2020.10.075"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0033","doi-asserted-by":"crossref","unstructured":"Beyzaee AM, Rahmatpour Rokni G, Patil A, Goldust M. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: a narrative review. Dermatol Ther, in press. doi:10.1111\/dth.14405.","DOI":"10.1111\/dth.14405"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0034","doi-asserted-by":"crossref","unstructured":"Elmas \u00d6.F, Demirba\u015f A, T\u00fcrsen \u00dc, Atasoy M, Lotti T. Pemphigus and COVID-19: critical overview of management with a focus on treatment choice. Dermatol Ther, in press. doi:10.1111\/dth.14265.","DOI":"10.1111\/dth.14265"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0036","first-page":"1080","article-title":"Bullous pemphigoid, a dermatosis of the elderly [in French]","volume":"67","author":"H\u00e9bert","year":"2017","journal-title":"Rev Prat"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0037","unstructured":"Centers for Disease Control and Prevention. Coronavirus disease 2019. Available at: https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2020.1800565?needAccess=true. Accessed March 23, 2020."},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0038","series-title":"Emergency Dermatology","first-page":"210","article-title":"Acute, severe bullous dermatoses","author":"Vassileva","year":"2016"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0039","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clindermatol.2013.11.003","article-title":"Autoimmune blistering diseases as systemic diseases","volume":"32","author":"Vassileva","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0040","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0041","doi-asserted-by":"crossref","first-page":"e13697","DOI":"10.1111\/dth.13697","article-title":"Patients with bullous disorders during COVID-19 period: management and adherence to treatment","volume":"33","author":"De Fata Salvatores","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0042","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0043","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0044","doi-asserted-by":"crossref","first-page":"e13956","DOI":"10.1111\/dth.13956","article-title":"Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era","volume":"33","author":"Azimi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109768","article-title":"Dapsone and doxycycline could be potential treatment modalities for COVID-19","volume":"140","author":"Farouk","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0046","doi-asserted-by":"crossref","first-page":"e14361","DOI":"10.1111\/dth.14361","article-title":"Immunobullous diseases, prothrombotic state, and COVID-19: role of prophylactic anticoagulation in bullous pemphigoid and pemphigus","volume":"33","author":"Anuragi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0047","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","article-title":"Mucous membrane pemphigoid [in German]","volume":"69","author":"Holtsche","year":"2018","journal-title":"Hautarzt"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0048","first-page":"49","article-title":"Pemphigoid\u2014bullous, cicatricial and gestationis [in Bulgarian]","volume":"3","author":"Manuelyan","year":"2013","journal-title":"Medicart"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0049","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/09546634.2020.1764472","article-title":"Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report","volume":"31","author":"Daneshpazhooh","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0050","doi-asserted-by":"crossref","unstructured":"Amir Dastmalchi D., Moslemkhani S., Bayat M., et\u00a0al. The efficacy of rituximab in patients with mucous membrane pemphigoid. J Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1801974.","DOI":"10.1080\/09546634.2020.1801974"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109774","article-title":"Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)","volume":"141","author":"Altschuler","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0052","doi-asserted-by":"crossref","first-page":"e14194","DOI":"10.1111\/dth.14194","article-title":"Novel coronavirus 2019 (COVID-19) and epidermolysis bullosa: report of three cases","volume":"33","author":"Abdollahimajd","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0053","unstructured":"Bodemer C, Bauer J, Bolling MC, et\u00a0al. Patients with rare skin diseases and COVID-19. European Reference Networks. Available at: https:\/\/ern-skin.eu\/covid-19\/. Accessed November 10, 2020."},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0054","doi-asserted-by":"crossref","unstructured":"Vahidnezhad H., Moravvej H., Bahmanjahromi A., Youssefian L., Abdollahimajd F. Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations. J Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1788701.","DOI":"10.1080\/09546634.2020.1788701"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0055","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jaad.2020.06.1023","article-title":"Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-consensus: recommendations by an international panel of experts","volume":"83","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0056","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0057","doi-asserted-by":"crossref","first-page":"e13495","DOI":"10.1111\/dth.13695","article-title":"Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy","volume":"33","author":"Brunasso","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0058","doi-asserted-by":"crossref","unstructured":"Chen P, Zhang G, Zhan Y. Management strategies of autoimmune bullous diseases during the outbreak of 2019 novel coronavirus disease (COVID-19). J Dermatolog Treat, in press. doi:10.1080\/09546634.2020.1771261.","DOI":"10.1080\/09546634.2020.1771261"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0059","doi-asserted-by":"crossref","first-page":"e000369","DOI":"10.1136\/lupus-2020-000396","article-title":"Thoughts on COVID-19 and autoimmune diseases","volume":"7","author":"Askanase","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0060","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/jdv.16525","article-title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"34","author":"Kasperkiewicz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0061","unstructured":"European Academy of Dermatology and Venereology. Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic. Available at: https:\/\/www.eadv.org\/covid-19\/task-force. Accessed November 10, 2020."},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0062","unstructured":"International Pemphigus & Pemphigoid Foundation. Information for pemphigus and pemphigoid patients related to coronavirus disease (COVID-19). Available at: http:\/\/www.pemphigus.org\/information-for-pemphigus-and-pemphigoid-patients-related-to-coronavirus-disease-covid-19\/. Accessed November 10, 2020."},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0063","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response. Available at: https:\/\/www.nice.org.uk\/guidance\/ng169. Accessed November 10, 2020."},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0064","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jaad.2020.04.045","article-title":"The American Academy of Dermatology COVID-19 registry: crowdsourcing dermatology in the age of COVID-19","volume":"83","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2021.01.007_bib0065","first-page":"795","article-title":"COVID-19 and immunological regulations-from basic and translational aspects to clinical implications","volume":"18","author":"Sch\u00f6n","year":"2020","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:56Z","timestamp":1760033876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X21000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0738081X21000079"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.01.007","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of COVID-19 on autoimmune blistering diseases","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}